search
Back to results

Theranova Randomized, Controlled, Trial (RCT) in China

Primary Purpose

Chronic Kidney Failure, Acute Kidney Failure

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Theranova 400 Dialyzer
FX 800 Dialyzer
Sponsored by
Baxter Healthcare Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Kidney Failure

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients aged ≥18 years old and ≤80 years old, regardless of gender;
  2. Patients who are able to sign informed consent form (ICF) after an explanation of the proposed study;
  3. Patients who receive in-center HD treatment at a site that routinely implements high flux dialysis and HDF;
  4. Patients who have been stable receiving in-center HD/HDF for >3 months prior to study enrollment;
  5. Patients with kidney failure receiving maintained HD treatment with a history of thrice weekly HD, and at least 1 HDF session within 1 month prior to the study shall be judged by the investigator;
  6. Patients who have an adequate arteriovenous (AV) fistula or graft, or dual-lumen tunneled catheter capable of providing a blood flow rate (QB) of at least 250 mL/min;
  7. Patients have no changes in dialysis prescription (dialyzer, time, dialysis fluid flow rate (QD), QB, sufficient dialysis anticoagulation, and stable prescribed doses) over last 6 treatments as judged by the investigator. The dialysis treatment time should be 3.5 to 4.5 hours per session with minimum QB of 250 mL/min and QD of 500 mL/min;
  8. Patients with a minimum total convective volume (including ultrafiltration (UF)) of 16 L post-dilution for the most recent HDF treatment;
  9. Patients who have Kt/Vurea > 1.2 for the last 2 measurements, with the most recent Kt/Vurea measurement taken within 4 weeks before or during study screening.

Exclusion Criteria:

  1. Patients who have acute kidney injury with the chance for recovery;
  2. Pregnant and lactating women;
  3. Patients diagnosed with a New York Heart Association (NYHA) Class IV congestive heart failure, or acute coronary syndrome, and/or who have suffered a myocardial infarction within 3 months prior to the start of the study;
  4. Patients with known hemodynamic instability, anemia (hemoglobin <90 g/L), and/or patients with hemoglobin >130g/L for coagulation risk;
  5. Patients with active or ongoing infection as per investigator's judgement (e.g C-reactive protein [CRP] level more than 5 folds of normal);
  6. Patients who are severely malnourished or with significant disease that interferes with liver synthetic function ( e.g. with serum albumin <30 g/L);
  7. Patients with positive serology tests for Hepatitis B surface antigen, Hepatitis C total antibody, and advanced liver, or pulmonary disease as judged by the investigator;
  8. Patients with positive serology tests for human immunodeficiency virus (HIV), Syphilis;
  9. Patients receiving immunosuppressive treatment or with autoimmune disease;
  10. Patients with a history of solid tumors requiring anti-cancer therapy in the past or next 6 months, or with a life expectancy of <1 year, or patients with history of hematology neoplasm;
  11. Patients who are pre-scheduled for a living donor kidney transplant within the next 1 year, who plan a change to peritoneal dialysis (PD) within the next 1 year, or who require single-needle dialysis therapy;
  12. Patients who have had an allergic response to polyarylethersulfone (PAES) or polysulfone (PS) membrane or have history of poor tolerance to dialyzers with synthetic membranes;
  13. Patients with a history of severe mental disorders who are unable to provide consent or comply with study procedures as assessed by the investigator;
  14. Patients who are currently participating in or have previously participated in other interventional clinical studies during the past 30 days;
  15. Patients with any comorbidity possibly conflicting with the study as judged by the investigator.

Sites / Locations

  • Baxter Investigational SiteRecruiting
  • Baxter Investigational SiteRecruiting
  • Baxter Investigational SiteRecruiting
  • Baxter Investigational SiteRecruiting
  • Baxter Investigational SiteRecruiting
  • Baxter Investigational SiteRecruiting
  • Baxter Investigational SiteRecruiting
  • Baxter Investigational SiteRecruiting
  • Baxter Investigational SiteRecruiting
  • Baxter Investigational SiteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Theranova 400 Dialyzer

FX 800 Dialyzer

Arm Description

1 week, 1 session in mid-week HD therapy. Pre dialysis blood samples taken from fistula needle or central venous catheter. Post dialysis blood samples taken from arterial sampling port of bloodline

1 week, 1 session in mid-week HDF therapy. Pre dialysis blood samples taken from fistula needle or central venous catheter. Post dialysis blood samples taken from arterial sampling port of bloodline

Outcomes

Primary Outcome Measures

Reduction ratio of lambda free light chains (λ FLC)
One mid-week treatment day dialysis session, pre-dialysis and post-dialysis
Reduction ratio of beta-2 microglobulin (β2-MG)
One mid-week treatment day dialysis session, pre-dialysis and post-dialysis

Secondary Outcome Measures

Assessment of Kt/V urea
One mid-week treatment day dialysis session, pre-dialysis and post-dialysis
Urea Reduction Ratio (URR)
One mid-week treatment day dialysis session, pre-dialysis and post-dialysis
Reduction ratio of α1 microglobulin (α1-MG)
One mid-week treatment day dialysis session, pre-dialysis and post-dialysis
Reduction ratio of Chitinase-3-like protein (YKL-40)
One mid-week treatment day dialysis session, pre-dialysis and post-dialysis
Reduction ratio of complement factor D (CFD)
One mid-week treatment day dialysis session, pre-dialysis and post-dialysis
Reduction ratio of myoglobin
One mid-week treatment day dialysis session, pre-dialysis and post-dialysis
Reduction ratio of kappa free light chains (κ FLC)
One mid-week treatment day dialysis session, pre-dialysis and post-dialysis

Full Information

First Posted
March 25, 2022
Last Updated
April 3, 2023
Sponsor
Baxter Healthcare Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT05309291
Brief Title
Theranova Randomized, Controlled, Trial (RCT) in China
Official Title
A Randomized, Controlled, Open-label, Parallel, Multicenter Study in Kidney Failure Patients on Hemodialysis Comparing the Theranova Dialyzer to Hemodiafiltration
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 29, 2022 (Actual)
Primary Completion Date
September 30, 2023 (Anticipated)
Study Completion Date
September 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Baxter Healthcare Corporation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Traditional HD therapy is very effective in clearing urea and smaller middle molecules, but is limited in clearing larger middle molecules. These accumulated large middle-molecular-weight uremic toxins may cause and aggravate inflammation, atherosclerosis and calcification, which indirectly lead to the death of patients. Studies have shown that, compared to conventional high-flux HD (HF-HD), HDF that combines diffusion and convection can reduce the all-cause mortality. Compared to the conventional HF-HD, HDF can more effectively clear larger molecular toxins in one session, which may be related to the better clearance effect of HDF on middle-molecular-weight toxins Theranova's innovative Medium Cut-Off® membranes has high permeability and selectivity to uremic toxins (clearance of a molecular weight of up to 45 kDa) and can retain essential proteins, to maintain patient's albumin level during the HD treatment[9]. Its unique membrane and high cut-off characteristics expand the clearance range beyond those of flux membrane dialyzers. Theranova 400 can be widely used in most blood purification centers under conventional HD equipment and treatment modes, with the effect similar to HDF This study is to demonstrate non-inferiority of the Theranova 400 Dialyzer in hemodialysis (HD) mode (hereinafter referred to as Theranova 400) compared to hemodiafiltration (HDF), using FX 800 in HDF mode (hereinafter referred to as FX 800).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Kidney Failure, Acute Kidney Failure

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
272 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Theranova 400 Dialyzer
Arm Type
Experimental
Arm Description
1 week, 1 session in mid-week HD therapy. Pre dialysis blood samples taken from fistula needle or central venous catheter. Post dialysis blood samples taken from arterial sampling port of bloodline
Arm Title
FX 800 Dialyzer
Arm Type
Active Comparator
Arm Description
1 week, 1 session in mid-week HDF therapy. Pre dialysis blood samples taken from fistula needle or central venous catheter. Post dialysis blood samples taken from arterial sampling port of bloodline
Intervention Type
Device
Intervention Name(s)
Theranova 400 Dialyzer
Other Intervention Name(s)
Hollow fiber dialyzers with medium cut-off membrane
Intervention Description
Dialysis performed in HD mode.
Intervention Type
Device
Intervention Name(s)
FX 800 Dialyzer
Other Intervention Name(s)
Hollow fiber hemodialysis filter
Intervention Description
Dialysis performed in HDF mode.
Primary Outcome Measure Information:
Title
Reduction ratio of lambda free light chains (λ FLC)
Description
One mid-week treatment day dialysis session, pre-dialysis and post-dialysis
Time Frame
Up to 1 week
Title
Reduction ratio of beta-2 microglobulin (β2-MG)
Description
One mid-week treatment day dialysis session, pre-dialysis and post-dialysis
Time Frame
Up to 1 week
Secondary Outcome Measure Information:
Title
Assessment of Kt/V urea
Description
One mid-week treatment day dialysis session, pre-dialysis and post-dialysis
Time Frame
Up to 1 week
Title
Urea Reduction Ratio (URR)
Description
One mid-week treatment day dialysis session, pre-dialysis and post-dialysis
Time Frame
Up to 1 week
Title
Reduction ratio of α1 microglobulin (α1-MG)
Description
One mid-week treatment day dialysis session, pre-dialysis and post-dialysis
Time Frame
Up to 1 week
Title
Reduction ratio of Chitinase-3-like protein (YKL-40)
Description
One mid-week treatment day dialysis session, pre-dialysis and post-dialysis
Time Frame
Up to 1 week
Title
Reduction ratio of complement factor D (CFD)
Description
One mid-week treatment day dialysis session, pre-dialysis and post-dialysis
Time Frame
Up to 1 week
Title
Reduction ratio of myoglobin
Description
One mid-week treatment day dialysis session, pre-dialysis and post-dialysis
Time Frame
Up to 1 week
Title
Reduction ratio of kappa free light chains (κ FLC)
Description
One mid-week treatment day dialysis session, pre-dialysis and post-dialysis
Time Frame
Up to 1 week

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients aged ≥18 years old and ≤80 years old, regardless of gender; Patients who are able to sign informed consent form (ICF) after an explanation of the proposed study; Patients who receive in-center HD treatment at a site that routinely implements high flux dialysis and HDF; Patients who have been stable receiving in-center HD/HDF for >3 months prior to study enrollment; Patients with kidney failure receiving maintained HD treatment with a history of thrice weekly HD, and at least 1 HDF session within 1 month prior to the study shall be judged by the investigator; Patients who have an adequate arteriovenous (AV) fistula or graft, or dual-lumen tunneled catheter capable of providing a blood flow rate (QB) of at least 250 mL/min; Patients have no changes in dialysis prescription (dialyzer, time, dialysis fluid flow rate (QD), QB, sufficient dialysis anticoagulation, and stable prescribed doses) over last 6 treatments as judged by the investigator. The dialysis treatment time should be 3.5 to 4.5 hours per session with minimum QB of 250 mL/min and QD of 500 mL/min; Patients with a minimum total convective volume (including ultrafiltration (UF)) of 16 L post-dilution for the most recent HDF treatment; Patients who have Kt/Vurea > 1.2 for the last 2 measurements, with the most recent Kt/Vurea measurement taken within 4 weeks before or during study screening. Exclusion Criteria: Patients who have acute kidney injury with the chance for recovery; Pregnant and lactating women; Patients diagnosed with a New York Heart Association (NYHA) Class IV congestive heart failure, or acute coronary syndrome, and/or who have suffered a myocardial infarction within 3 months prior to the start of the study; Patients with known hemodynamic instability, anemia (hemoglobin <90 g/L), and/or patients with hemoglobin >130g/L for coagulation risk; Patients with active or ongoing infection as per investigator's judgement (e.g C-reactive protein [CRP] level more than 5 folds of normal); Patients who are severely malnourished or with significant disease that interferes with liver synthetic function ( e.g. with serum albumin <30 g/L); Patients with positive serology tests for Hepatitis B surface antigen, Hepatitis C total antibody, and advanced liver, or pulmonary disease as judged by the investigator; Patients with positive serology tests for human immunodeficiency virus (HIV), Syphilis; Patients receiving immunosuppressive treatment or with autoimmune disease; Patients with a history of solid tumors requiring anti-cancer therapy in the past or next 6 months, or with a life expectancy of <1 year, or patients with history of hematology neoplasm; Patients who are pre-scheduled for a living donor kidney transplant within the next 1 year, who plan a change to peritoneal dialysis (PD) within the next 1 year, or who require single-needle dialysis therapy; Patients who have had an allergic response to polyarylethersulfone (PAES) or polysulfone (PS) membrane or have history of poor tolerance to dialyzers with synthetic membranes; Patients with a history of severe mental disorders who are unable to provide consent or comply with study procedures as assessed by the investigator; Patients who are currently participating in or have previously participated in other interventional clinical studies during the past 30 days; Patients with any comorbidity possibly conflicting with the study as judged by the investigator.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Baxter Clinical Trials Disclosure Call Center
Phone
(224) 948-7359
Email
Global_CORP_ClinicalTrialsDisclosure@baxter.com
Facility Information:
Facility Name
Baxter Investigational Site
City
Beijing
ZIP/Postal Code
100013
Country
China
Individual Site Status
Recruiting
Facility Name
Baxter Investigational Site
City
Beijing
ZIP/Postal Code
100034
Country
China
Individual Site Status
Recruiting
Facility Name
Baxter Investigational Site
City
Dalian
ZIP/Postal Code
116001
Country
China
Individual Site Status
Recruiting
Facility Name
Baxter Investigational Site
City
Dalian
ZIP/Postal Code
116011
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Baxter I Site
Facility Name
Baxter Investigational Site
City
Hangzhou
ZIP/Postal Code
310014
Country
China
Individual Site Status
Recruiting
Facility Name
Baxter Investigational Site
City
Nanjing
ZIP/Postal Code
210002
Country
China
Individual Site Status
Recruiting
Facility Name
Baxter Investigational Site
City
Shanghai
ZIP/Postal Code
200011
Country
China
Individual Site Status
Recruiting
Facility Name
Baxter Investigational Site
City
Shanghai
ZIP/Postal Code
200127
Country
China
Individual Site Status
Recruiting
Facility Name
Baxter Investigational Site
City
Shenzhen
ZIP/Postal Code
518020
Country
China
Individual Site Status
Recruiting
Facility Name
Baxter Investigational Site
City
Suzhou
ZIP/Postal Code
215006
Country
China
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Sharing of Clinical Trial Data: Baxter is committed to sharing clinical trial data with external medical experts and scientific researchers in the interest of advancing public health. As such, Baxter will supply anonymized Individual Patient Datasets (IPD) and supporting documents (synopsis of clinical study reports, protocol and SAP's)
IPD Sharing Time Frame
Upon approval of a legitimate research request.
IPD Sharing Access Criteria
Research requests will be reviewed by qualified medical and scientific experts within the company. If Baxter agrees to the release of clinical data for research purposes, the requestor will be required to sign a data sharing agreement (DSA) in order to ensure protection of patient confidentiality and any intellectual property rights of Baxter prior to the release of any data.
IPD Sharing URL
https://www.baxter.com/clinical-trial-transparency-and-data-sharing-policy

Learn more about this trial

Theranova Randomized, Controlled, Trial (RCT) in China

We'll reach out to this number within 24 hrs